{"schema_version":"secwatch.filing_event.v1","accession":"0000920148-25-000075","form_type":"8-K","ticker":"LH","cik":"0000920148","company_name":"LABCORP HOLDINGS INC.","filed_at":"2025-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.702348+00:00","generated_at":"2026-05-18T03:01:31.521415+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Labcorp Q2 revenue $3.53B, Adj EPS $4.35; raises full-year guidance","bullets":["Q2 revenue $3.53B (+9.5% YoY); diluted EPS $2.84 vs $2.43; adjusted EPS $4.35 vs $3.94.","Full-year guidance raised: revenue growth 7.5%-8.6%; adjusted EPS $16.05-$16.50; FCF $1.13-$1.28B.","Diagnostics Labs revenue $2.75B (+8.9%); Biopharma Lab Services $784.8M (+11.0%).","Quarterly dividend $0.72/share declared; $200M stock repurchased in Q2.","Announced acquisitions of select assets from Incyte Diagnostics, BioReference Health, and Community Health Systems."],"urls":{"canonical":"https://secwatch.observer/filing/0000920148-25-000075","json":"https://secwatch.observer/filing/0000920148-25-000075.json","markdown":"https://secwatch.observer/filing/0000920148-25-000075.md","text":"https://secwatch.observer/filing/0000920148-25-000075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/920148/000092014825000075/0000920148-25-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/920148/000092014825000075/lh-20250724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T03:01:31.521415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}